Seegene AllplexTM2019-nCoV Assay shows excellent performance in the recent FIND evaluation

We are pleased to share with you the excellent results of the AllplexTM2019-nCoV Assay from Seegene, which was very recently compared against other SARS-CoV-2 molecular assays, in the FIND evaluation.
FIND conducted independent evaluations at the University Hospitals of Geneva (HUG), to verify the limit of detection (LOD) and the clinical performance of so far 10 molecular test kits detecting SARS-CoV-2.

The AllplexTM2019-nCoV Assay from Seegene could achive 100% Clinical sensitivity and 100% Clinical specificity for all three target genes (E gene, RdRP gene, N gene).
In this first evaluation round, the automated Seegene AllplexTM2019-nCoV Assay is so far the only multiplexed test that can detect these three target genes simultaneously in one tube.
Please click on the link below to find the performance data of all COVID-19 MDx tests, which have been evaluated by FIND so far: